Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Boekhout AH, Rogiers A, Jozwiak K, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Ten Tije AJ, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Rozeman EA, Neyns B, Janssen KJ, van de Poll-Franse LV, Blank CU. Boekhout AH, et al. Acta Oncol. 2021 Jan;60(1):69-77. doi: 10.1080/0284186X.2020.1818823. Epub 2020 Sep 14. Acta Oncol. 2021. PMID: 32924708
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
Mulder EEAP, de Joode K, Litière S, Ten Tije AJ, Suijkerbuijk KPM, Boers-Sonderen MJ, Hospers GAP, de Groot JWB, van den Eertwegh AJM, Aarts MJB, Piersma D, van Rijn RS, Kapiteijn E, Vreugdenhil G, van den Berkmortel FWPJ, Hoop EO, Franken MG, Ryll B, Rutkowski P, Sleijfer S, Haanen JBAG, van der Veldt AAM. Mulder EEAP, et al. BMC Cancer. 2021 Mar 25;21(1):323. doi: 10.1186/s12885-021-08018-w. BMC Cancer. 2021. PMID: 33765967 Free PMC article.
Survival of stage IV melanoma in Belgium and the Netherlands.
Suijkerbuijk KPM, Haanen JBAG, Boers-Sonderen MJ, Hospers GAP, Blank CU, van den Berkmortel FWPJ, de Groot JWB, Piersma D, Aarts MJB, van Rijn RS, Vreugdenhil G, Westgeest HM, Kapiteijn E, van der Veldt AAM, van den Eertwegh AJM. Suijkerbuijk KPM, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e118-e119. doi: 10.1111/jdv.17668. Epub 2021 Sep 30. J Eur Acad Dermatol Venereol. 2022. PMID: 34536304 No abstract available.
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.
Franken MG, Leeneman B, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Suijkerbuijk KPM, van der Veldt AAM, Westgeest HM, Wouters MWJM, Haanen JBAG, Uyl-de Groot CA. Franken MG, et al. ESMO Open. 2021 Dec;6(6):100320. doi: 10.1016/j.esmoop.2021.100320. Epub 2021 Nov 29. ESMO Open. 2021. PMID: 34856511 Free PMC article.
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Stillebroer AB, et al. Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21. Eur Urol. 2013. PMID: 22980441 Clinical Trial.
Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma.
Ter Maat LS, De Mooij RAJ, Van Duin IAJ, Verhoeff JJC, Elias SG, Leiner T, van Amsterdam WAC, Troenokarso MF, Arntz ERAN, Van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, Van den Eertwegh FJM, de Groot JW, Hospers GAP, Piersma D, Vreugdenhil A, Westgeest HM, Kapiteijn E, De Wit AA, Blokx WAM, Van Diest PJ, De Jong PA, Pluim JPW, Suijkerbuijk KPM, Veta M. Ter Maat LS, et al. Among authors: boers sonderen mj. Sci Rep. 2024 Dec 30;14(1):31668. doi: 10.1038/s41598-024-81188-2. Sci Rep. 2024. PMID: 39738216 Free PMC article.
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. Özkan A, et al. Among authors: boers sonderen mj. Eur J Cancer. 2024 Dec 26;216:115194. doi: 10.1016/j.ejca.2024.115194. Online ahead of print. Eur J Cancer. 2024. PMID: 39732138 No abstract available.
79 results